CAR-T – Page 2 – Talk Bio

Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition

7 months ago talkbio0Tagged Allogene, Breyanzi, CAR-T, cema-cel, Clinical Trials, leukemia, Myers, squibb

Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials

Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti

7 months ago talkbio0Tagged 2024, Arcellx, Asymmetric Septal Hypertrophy, CAR-T, Carvykti, Effectiveness, Gilead, Multiple Myeloma, relapsed/refractory multiple myeloma, safety profile

Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma

AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy

8 months ago talkbio0Tagged AvenCell Therapeutics, biotech, CAR-T, CAR-Ts, Cell Therapy, Clinical Trials, innovation, Series B, Switchable

AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation

J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment

8 months ago talkbio0Tagged Benefit, CAR-T, CARTITUDE-4, Carvykti, Continuance of life, Johnson & Johnson, Legend Biotech, Multiple Myeloma, second-line

Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment

Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun

9 months ago talkbio0Tagged CAR-T, Cell Therapy, China, Fosun Pharma, Gilead Sciences, Joint Ventures, Kite Pharma, Yescarta

Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta

Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma

9 months ago talkbio0Tagged CAR-T, Cell Therapy, China, Fosun Pharma, Gilead Sciences, Joint Ventures, Kite Pharma, Yescarta

Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta

ArsenalBio Secures $325M Funding to Advance Programmable CAR-T Therapies

9 months ago talkbio0Tagged ArsenalBio, Burning Mouth Syndrome, CAR-T, Cell Therapy, Regeneron, Solid Neoplasm

ArsenalBio, CAR-T therapies, biotech funding, programmable cell therapies, solid tumors, Regeneron, BMS

Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events

10 months ago talkbio0Tagged Adverse event, amgen, Antibodies, Bispecific, CAR-T, Carvykti, China, Curon Biopharmaceutical, Evaluation procedure, File (record), Legend Biotech, Merck, United States Food and Drug Administration

Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti

Precigen Restructures, Reduces CAR-T Efforts Amid Job Cuts

10 months ago talkbio0Tagged AdenoVerse, CAR-T, gene therapy, Precigen, restructuring

Precigen, CAR-T, restructuring, job cuts, UltraCAR-T, gene therapy, AdenoVerse, PRGN-2012

Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case

10 months ago talkbio0Tagged bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CAR-T, Clinical Trials, Galapagos, GLPG5301, Multiple Myeloma, PAPILIO-1, Parkinsonian Disorders

Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301